Objective: This follow-up study of the European Dexamethasone Study was designed to examine the potential harmful effect of adjunctive dexamethasone treatment on long-term neuropsychological outcome in adults with bacterial meningitis. Methods: Neurological, audiological, and neuropsychological examinations were performed in adults who survived pneumococcal or meningococcal meningitis. Results: Eighty-seven of 99 (88%) eligible patients were included in the follow-up study; 46 (53%) were treated with dexamethasone and 41 (47%) with placebo. Median time between meningitis and testing was 99 months. Neuropsychological evaluation showed no significant differences between patients treated with dexamethasone and placebo. The proportions of patients with persisting neurological sequelae or hearing loss were similar in the dexamethasone and placebo groups. The overall rate of cognitive dysfunction did not differ significantly between patients and control subjects; however, patients after pneumococcal meningitis had a higher rate of cognitive dysfunction (21 vs 6%; p ϭ 0.05) and experienced more impairment of everyday functioning due to physical problems (p ϭ 0.05) than those after meningococcal meningitis. Interpretation: Treatment with adjunctive dexamethasone is not associated with an increased risk for long-term cognitive impairment. Adults who survive pneumococcal meningitis are at significant risk for long-term neuropsychological abnormalities.
The estimated incidence of bacterial meningitis is 2 to 5 per 100,000 adults per year. [1] [2] [3] The predominant causative pathogens in adults are Streptococcus pneumoniae and Neisseria meningidis, which cause 80 to 85% of all cases. 1, 4 Reported mortality rates are high (20 -30%), and neurological sequelae occur in a high proportion of surviving patients (15-40%). 1, 4 Cognitive impairment occurs frequently after bacterial meningitis. 2 In one prospective study, cognitive impairment was detected in 27% of adults who had a good recovery from pneumococcal meningitis. 5 In this study, cognitive impairment consisted mainly of cognitive slowness, which was related to lower scores on questionnaires measuring the quality of life. Patients after meningococcal meningitis were not significantly different from control subjects. 5 A European randomized, placebo-controlled trial involving 301 adults with suspected meningitis showed that adjunctive treatment with dexamethasone before or with the first dose of antimicrobial therapy reduced the risk for an unfavorable outcome from 25 to 15%. 6 Mortality was reduced from 15 to 7%. In a recent quantitative review of this topic, treatment with corticosteroids was associated with a significant reduction in mortality and neurological sequelae. 7 Since publications of these results, adjunctive dexamethasone has become routine therapy in adults with suspected bacterial meningitis. 2, 6, 8 Corticosteroids may potentiate ischemic and apoptotic injury to neurons. 9 In a model of pneumococcal meningitis in infant rats, adjunctive dexamethasone aggravated neuronal apoptosis in the hippocampal dentate compared with antibiotic therapy alone. 10 Increased hippocampal cell injury caused by dexamethasone was related to a reduced learning capacity in this model. 10 The effect of adjunctive dexamethasone therapy on cognitive outcome in humans after bacterial meningitis is unknown. 2, 7, [11] [12] [13] [14] This study was designed to examine the potential harmful effects of adjunctive dexamethasone treatment on long-term cognitive outcome in patients with bacterial meningitis. Therefore, neurological, audiological, and neuropsychological examinations were performed in adults included in the European Dexamethasone Study after pneumococcal or meningococcal meningitis.
Subjects and Methods

Initial Study
The European Dexamethasone Study was a double-blind, placebo-controlled trial of adjunctive dexamethasone therapy for adults with bacterial meningitis. Eligible patients were older than 17 years and had suspected meningitis in combination with cloudy cerebrospinal fluid (CSF), bacteria in CSF on Gram staining, or a CSF leukocyte count greater than 1,000/mm 3 . 6 Patients were enrolled between June 1993 and December 2001. A total of 301 patients were randomly assigned to receive dexamethasone sodium phosphate, at a dose of 10mg given every 6 hours intravenously for 4 days, or placebo. The study medication was given 15 to 20 minutes before or with the first dose of antibiotics. The primary outcome measure was the score on the Glasgow Outcome Scale (GOS) 8 weeks after randomization, as assessed by the patient's physician. This is a well-validated measurement scale with a score range from 1 to 5: a score of 1 indicates death; 2 is persistent vegetative state; 3 is severe disability; 4 is moderate disability (disabled but independent); and 5 is good recovery (mild or no disability). 15 A favorable outcome was defined as a score of 5, and an unfavorable outcome as a score of 1 to 4. CSF culture yielded S. pneumoniae in 108 patients (36%), N. meningitidis in 97 patients (32%), and other bacteria in 31 patients (10%); CSF cultures remained negative in 65 patients (22%). Treatment with dexamethasone was associated with a reduction in the risk for an unfavorable outcome (relative risk, 0.6; 95% confidence interval, 0.3-0.9; p ϭ 0.03) and mortality (relative risk, 0.48; 95% confidence interval, 0.2-0.96; p ϭ 0.04). 6 
Follow-up Study
Patients eligible for this follow-up study were older than 17 years living in the Netherlands who survived pneumococcal or meningococcal meningitis, confirmed by CSF culture. Exclusion criteria were serious illnesses other than meningitis interfering with cognitive testing, pre-existing psychiatric disorders, evidence for alcoholism or other substance abuse, use of sedatives or neuroleptic medication, and insufficient mastery of the Dutch language. Patients were recruited by contacting treating physicians, general practitioners, or through municipality databases. The study was approved by the ethics committee of the Academic Medical Center. For each of the participating patients, 1 control subject was recruited from partners, siblings, and close friends until a control group of 50 subjects was completed. All participants gave written, informed consent. Patients and control subjects underwent a tone and speech audiogram and a neuropsychological evaluation by a psychologist (M.H.) who was blinded with respect to the former treatment group (dexamethasone or placebo). Whenever audiometry was performed, hearing loss was expressed as the average degree of pure-tone hearing loss of high frequencies (1, 2, and 4kHz) on the most severely affected side. Hearing loss was classified as follows: normal (Ͻ30dB), mild (Ն30 -55dB), moderate (Ն55-70dB), severe (Ն70 -90dB), or profound (Ն90dB). 16 Two experienced physicians (M.W. and D.v.d.B.) performed a neurological examination in patients. Focal neurological deficits were divided into focal cerebral deficits (aphasia, monoparesis, or hemiparesis) and cranial nerve palsies. Participants unable or unwilling to travel to our hospital underwent a neuropsychological evaluation by our psychologist in a hospital near the patients' residences.
Neuropsychological Evaluation
Six cognitive domains were tested by the following test battery: 19 General health and quality of life were evaluated by means of the RAND-36 questionnaire 23, 24 ; the Profile of Mood States (POMS) determined depressive mood disorders. 19 To explore whether measurement of cognitive speed was biased by physical impairments, we tested fine motor skills using the Grooved Pegboard. 25 These tests are described in the Appendix.
Test results were expressed as standard T-scores corrected for age and education with use of the control group to form normative scores for the neuropsychological measures (mean score in control subjects, 50; standard deviation, 10; a higher score indicates better performance). 26 
Data Analysis
To examine relative differences between groups, we performed multivariate analyses of variance (MANOVAs) within each neuropsychological domain separately using T-scores corrected for age and education. If multivariate comparisons demonstrated significant results ( p Ͻ 0.05, Pillais' Trace two-tailed), t tests with Bonferroni correction for the number of comparisons were performed to evaluate single neuropsychological measures.
As a next step, we tested for statistical interaction between treatment group (dexamethasone vs placebo) and the causative pathogen (S. pneumoniae vs N. meningitidis) by adding multiplicative interaction terms to the multivariate comparisons. Statistically significant interactions within a cognitive domain were analyzed by linear regression with the individual neuropsychological measure as the dependent variable and the interaction term as the independent variable. The strength of the associations between treatment and test results within each patient group was expressed as regression coefficients (a positive regression coefficient indicates a higher score in the subgroup treated with adjunctive dexamethasone than in those receiving placebo).
A test score was categorized as impaired if at least two standard deviations below the mean score of the control group, after correction for age and education. Cognitive dysfunction was considered to be present if performance, reflected by the number of impaired test results, was worse than the fifth centile of the control group. To compare cognitive speed between groups, we formed a speed composite score for each participant by calculation of a mean T-score of tests in which cognitive speed is important, as described previously. 5, 27 Cognitive slowness was defined as a speed composite score worse than the fifth centile of the control group, after correction for age and education.
We hypothesized the existence of clinically significant cognitive impairment for patients who recovered from bacterial meningitis, with higher rates of cognitive impairment in patients receiving adjunctive dexamethasone than in those treated with placebo. 2, 10 In addition, we hypothesized higher rates of cognitive impairment in survivors of pneumococcal meningitis compared with those after meningococcal meningitis. 5 For nonparametric testing, Mann-Whitney U, 2 
Role of the Funding Source
The funding source had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit this article for publication.
Results
In the European study, 32 of 301 patients (11%) died within 8 weeks after admission. Of 269 surviving patients, 177 (66%) had bacterial meningitis due to S. pneumoniae (n ϭ 83) or N. meningitidis (n ϭ 94), as proved by CSF culture (Fig) ; 26 patients (15%) could not be reached. In addition, exclusion criteria were met in 52 patients: death (n ϭ 19), residence outside the Netherlands (n ϭ 11), somatic or psychiatric illnesses not related to meningitis that impair cognitive testing (n ϭ 17), history of alcoholism (n ϭ 2) or other substance abuse (n ϭ 1), insufficient mastery of the Dutch language (n ϭ 1), or age younger than 16 years (n ϭ 1; protocol violation of European study). In total, 99 patients were eligible for follow-up; of those eligible, 12 patients (12%) refused to participate (all had a GOS score of 5, as assessed by telephonic interview). Thus, 87 of 99 patients (88%) were included in this follow-up study. Demographic characteristics (age and sex), causative pathogens, and score on the GOS (8 weeks after discharge) were similar for eligible and participating patients. A total of 50 control subjects were recruited. Sex distribution (17 of 50 [34%] control subjects were male; 43 of 87 [49%] patients were male), age distribution (mean age, 49 Ϯ 15 years for control subjects vs 47 Ϯ 16 years for patients), and level of education (13.2 Ϯ 1.6 years for control subjects vs 12.9 Ϯ 2.3 years for patients) were similar in patients and control subjects.
Clinical characteristics at time of admission were similar in the dexamethasone-and placebo-treated groups (Table 1) . Focal neurological deficits were present in 23 of 87 patients (26%), and 10 patients (12%) were comatose on admission. CSF results demonstrated S. pneumoniae in 38 patients (44%) and N. meningitidis in 49 (56%); 46 patients (53%) received adjunctive dexamethasone and 41 (47%) received placebo. Eight weeks after discharge, focal neurological deficits were present in 12 of 87 patients (14%). Outcome was graded as favorable in 80 of 87 patients (92%); 6 (7%) patients had a GOS score of 4, and 1 patient (1%) had a score of 3.
Neurological examination was performed in all patients in this follow-up study. The median time between discharge and neurological examination was 99 months (range, 30 -146 months) and was similar in both treatment groups. Neurological deficits were present in 17 of 87 patients (20%); there were no differences between treatment groups (Table 2) . Eighty patients (92%) had a GOS score of 5, and 7 (8%) had a GOS score of 4. All patients with a GOS score of 4 had neurological sequelae; two patients had focal cerebral deficits, and the additional five patients had cranial nerve palsies. Ten patients (11%) had only slight hearing impairment without significant interference in daily life: These patients also received a GOS score of 5. Most patients had similar scores on the GOS compared with the evaluation 8 weeks after admission ( p ϭ 0.76). Patients after pneumococcal meningitis had a higher rate of focal neurological deficits and were more likely to have a GOS score of 4 than those after meningococcal meningitis.
Audiological examination was performed in all participants who were able/willing to travel to our hospital: 51 of 87 patients (59%) and 35 of 50 control subjects (70%; Table 3 ). The degree of hearing loss in survivors of bacterial meningitis was similar to that in Neuropsychological examination was performed in all patients and control subjects. Demographic characteristics and interval between meningitis and testing for patients treated with dexamethasone and placebo were similar (Table 4) . MANOVAs within neuropsychological domains showed no significant overall group differences between both treatment groups for "intelligence" ( p ϭ 0.06), "memory" ( p ϭ 0.15), "executive functioning" ( p ϭ 0.08), "attention" ( p ϭ 0.68), and "psychomotor speed" ( p ϭ 0.72). Both treatment groups also had similar scores on questionnaires for general health and quality of life (RAND-36). Patients who received adjunctive dexamethasone had higher scores on the item "depression" than those with placebo ( p ϭ 0.04); results of the multivariate analyses for the cognitive domains remained similar after correction for depression scores.
The number of impaired test results for both treatment groups was similar as well (Table 5 ). Based on performance in the control group, a patient was considered to have cognitive dysfunction if he or she had three or more impaired test results. According to these criteria, cognitive dysfunction was present in 4 of the 46 (9%) patients treated with dexamethasone compared with 7 of 41 patients in the placebo group (17%; p ϭ 0.24). Both treatment groups had similar results on the speed composite score ( p ϭ 0.14). Performance on the speed composite score showed no significant correlations with performance on the Grooved Pegboard and scores on the item "depression" of the POMS.
In patients with pneumococcal meningitis, demographic characteristics were similar in both treatment groups, although the interval between meningitis and testing was longer in those treated with dexamethasone ( p ϭ 0.04; Table 6 ). MANOVAs within neuropsychological domains showed significant overall group differences between both treatment groups for "memory" ( p ϭ 0.004) and "executive functioning" ( p ϭ 0.01), but not for "intelligence" ( p ϭ 0.52), "attention" ( p ϭ 0.68), and "psychomotor speed" ( p ϭ 0.86). Results of the multivariate analyses for the cognitive domains remained similar after correction for the interval between meningitis and testing. Pneumococcal meningitis patients who were treated with dexamethasone performed significantly better on the AVLT recognition than those treated with placebo ( p ϭ 0.004, Bonferroni correction). Performance on the other neuropsychological tests within the domains of "memory" and "executive functioning" was similar in both treatment groups.
In patients with meningococcal meningitis, demo- graphic characteristics in patients treated with dexamethasone and placebo were similar (Table 7) . MANOVAs within neuropsychological domains showed no significant overall group differences between both treatment groups for "intelligence" ( p ϭ 0.23), "memory" ( p ϭ 0.23), "executive functioning" ( p ϭ 0.50), "attention" ( p ϭ 0.99), and "psychomotor speed" ( p ϭ 0.32).
The interaction between the causative pathogen and treatment group was significant for the multivariate comparison of test results within the domain of "memory" ( p ϭ 0.007), but not within any of the other cognitive domains ( p Ͼ 0.55 for all). In a linear regression analysis, this interaction was significant for performance on two subtests of the AVLT. Dexamethasone therapy was associated with higher scores on the AVLT immediate recall in patients after pneumococcal meningitis and with lower scores on the same test in survivors of meningococcal meningitis; regression coefficient in the subgroup of pneumococcal patients was 0.23 compared with Ϫ0.25 within meningococcal patients ( p interaction ϭ 0.03). Similar associations were found for performance on the AVLT recognition (regression coefficient of 0.46 in pneumococcal patients vs Ϫ0.05 in meningococcal patients; p interaction ϭ 0.01). Control subjects and patients had similar scores on premorbid intelligence (99.6 Ϯ 18 in control subjects vs 99.5 Ϯ 17 in patients; p ϭ 0.96). MANOVAs showed no significant differences between patients and control subjects for "intelligence" ( p ϭ 0.37), "memory" ( p ϭ 0.31), "executive functioning" ( p ϭ 0.06), "attention" ( p ϭ 0.15), and "psychomotor speed" ( p ϭ 0.38). Both groups had similar scores on the RAND-36, the POMS, and the Grooved Pegboard.
Patients after pneumococcal meningitis were older ( p Ͻ 0.0001) and had a lower level of education ( p ϭ 0.01) than those after meningococcal meningitis (Table  8) . Sex distribution in both groups was similar. MANOVAs showed significant overall group differences between survivors of pneumococcal meningitis and meningococcal meningitis for "memory" ( p ϭ 0.01), but not for "intelligence" ( p ϭ 0.12), "executive functioning" ( p ϭ 0.08), "attention" ( p ϭ 0.12), and "psychomotor speed" ( p ϭ 0.22). Patients after pneumococcal meningitis performed worse than those after meningococcal meningitis on all tasks of the AVLT and the Wechsler Memory Scale-Revised. These differ- ences remained similar after correction for score on the speed composite measure, but they were no longer significant after Bonferroni correction for the number of comparisons. Patients who had pneumococcal meningitis experienced more impairment of everyday functioning due to physical problems (RAND-36; p ϭ 0.05). Both groups had similar scores on the Grooved Pegboard and the item "depression" of the POMS. The proportion of cognitive dysfunction was higher in patients after pneumococcal meningitis (8 of 38 [21%] vs 3 of 49 [6%]; p ϭ 0.05). Survivors of pneumococcal and meningococcal meningitis had similar results on the speed composite score ( p ϭ 0.09). Performance on the speed composite score was significantly associated with current intelligence in a linear regression analysis (intelligence quotient; p Ͻ 0.0001, two-tailed), but not with the causative pathogen ( p ϭ 0.10), time since meningitis ( p ϭ 0.67), dexamethasone therapy ( p ϭ 0.44), and GOS score ( p ϭ 0.86). Quality-of-life questionnaires demonstrated that patients who were defined as cognitively impaired had higher scores on the item "depression" of the POMS ( p ϭ 0.003) and had lower scores on the RAND-36 on the subscales of social functioning ( p ϭ 0.04), mental health ( p ϭ 0.004), and general health ( p ϭ 0.05). 
Discussion
Our results show that treatment with adjunctive dexamethasone is not associated with an increased risk for long-term cognitive impairment in adults with bacterial meningitis. Because adjunctive dexamethasone has become routine therapy in adults with suspected bacterial meningitis, this is important information for patients and their treating physicians. Our prospective study comprises the largest number of patients with longterm neurological and neuropsychological evaluation after bacterial meningitis to date and has enough power to detect relevant differences between the dexamethasone and placebo groups. Treatment with adjunctive dexamethasone is associated with a reduced risk for an unfavorable outcome, including mortality, in adults with bacterial meningitis. 6, 7 Although treatment with adjunctive dexamethasone was not associated with apparent side effects in the European study, concerns existed about the effects on long-term cognitive outcome. 13 In vitro studies have shown that corticosteroids are toxic to cultured hippocampal and cortical neurons. 28 Animal studies demonstrated that striatal and hippocampal neurons are particularly vulnerable to dexamethasone. 29, 30 In addition, dexamethasone therapy increased hippocampal apoptosis and learning deficiencies in experimental bacterial meningitis. 10, 31 The dosage of dexamethasone used in these experimental studies and the European study were similar (0.7mg/kg/day). 10 Corticosteroidinduced damage of hippocampal neurons may account for some of the cognitive deficits that have been noted in healthy volunteers. 29, 30 In a study on long-term effects of early postnatal dexamethasone therapy for lung disease of prematurity, steroids were associated with impairments in neuromotor and cognitive function at school age. 32 Our analyses showed no significant group differences between patients treated with adjunctive dexamethasone and placebo within any of the cognitive domains. Therefore, treatment with adjunctive dexamethasone does not worsen long-term cognitive outcome in adults after bacterial meningitis.
We found that 13% of the patients who survived bacterial meningitis had cognitive impairment. These results are identical to those of our previous study in which neuropsychological testing was performed in 51 adults with good recovery after bacterial meningitis. 5 A recent German study evaluating cognitive outcome 1 to 12 years after bacterial meningitis found a much higher rate of cognitive impairment (37%). 33 These differences are explained by different criteria for cognitive dysfunction. The German study used less strict criteria, resulting in impaired cognitive functioning of the control subjects ranging from 7 to 27% per domain. If our criteria for cognitive dysfunction (score worse than the fifth centile of control group) were applied to the German study, 10% of the patients in their study would have been rated as cognitively impaired. 33 Patients after pneumococcal meningitis are at high risk for cognitive impairment. Cognitive impairment was found in 21% of the patients who survived pneumococcal meningitis. Patients after meningococcal meningitis had scores similar to those of the control subjects. These findings agree with our previous study that found cognitive impairment in 27% of the adults who made a good recovery after pneumococcal meningitis. 5 The recent German study found no differences in cognitive outcome between survivors of pneumococcal and meningococcal meningitis 33 ; however, these discordant findings may well be explained by the limited number of patients in the latter study. 11 The main cognitive impairment in patients after pneumococcal meningitis consisted of memory deficits. Previous studies on cognitive outcome in adults who survived bacterial meningitis described cognitive slowness, impairment of psychomotor and visuoconstructive performance, and higher scores on depression scales. 5, 27, [33] [34] [35] Our findings agree with previous observations. 5, 27, 33 Hippocampal damage has been related to learning and memory deficits in humans and in animal models. 10 This suggests that neuronal apoptosis in the hippocampal dentate gyrus represents the major neuropathological process responsible for cognitive impairment in survivors of bacterial meningitis.
Cognitive speed was not related to time since meningitis. This is in contrast with our previous study, which suggested that loss of cognitive speed might be partially reversible in time. 27 This might well be explained by the longer time interval between meningitis and neuropsychological evaluation in this study compared with those previous studies (median , 8 27 respectively). Our findings imply that neuropsychological impairment improves in the first years after bacterial meningitis and becomes relatively stable with time.
The association of adjunctive dexamethasone therapy with test results within the domain of memory differed between patients after pneumococcal and meningococcal meningitis. Whereas patients after pneumococcal meningitis that received steroid therapy performed slightly better on several memory-dependent tasks than those in the placebo group, our analyses showed a reverse association in the subgroup of meningococcal patients. Although these findings may have been due to chance, they are in line with the conflicting results of steroids on neuronal injury in experimental meningitis studies. 10, 12, 36 Animal models of bacterial meningitis showed that a more severe inflammatory response within the subarachnoid space is associated with an increased risk for adverse outcome and neurological se-quelae.
Wisconsin Card Sorting Test (WCST):
This test uses a deck of cards on which different numbers of different forms in different colors are shown. The task is to sort the cards according to one of three possible sorting rules (color, number, or form). These rules are not told but must be determined by the subject. After each sort, feedback is given on whether it was correct. Once a sorting rule has been found (10 correct sorts on a row), the subject has to change to a different rule. Of particular interest are perseverative errors of the kind where the subject keeps sorting according to a previously correct rule or to a rule that was wrong in the immediately preceding sort. The WCST is a test of concept formation and set shifting. Scores used in this study are the raw numbers of errors and perseverations. GIT, Category Fluency: For 1 minute, the subject has to say as many words that belong to a particular semantic category. Two trials were done (animals and occupations).
Letter Fluency (Controlled Oral Word Association Test
[COWAT]): For 1 minute, the subject has to say as many words that begin with a given letter. Three trials with different letters were done. Simple reaction speed: Simple reaction speed was tested for the dominant and nondominant hands separately with use of visual stimuli. Scores are median reaction times in milliseconds. Two-choice reaction speed: Two-choice reaction speed was tested with use of both hands and visual stimuli. Scores are median reaction times in milliseconds. Grooved Pegboard: Fine motor skills and visual motor coordination were tested for the dominant and nondominant hands separately with use of a board with 25 holes with randomly positioned slots in which cones have to be inserted. Score is time to completion in seconds.
Subtest Digit Span of Wechsler Adult Intelligence ScaleRevised (WAIS-R):
Subjects have to listen to increasingly longer lists of digits and to produce immediate recall in the actual and in reverse order from initial presentation. This test is a measure of attention, as well as working memory.
RAND-36:
The RAND-36 is a questionnaire of general health and quality of life. It has been standardized for the Netherlands on a sample of subjects (n ϭ 1,063) that is roughly comparable with the present groups with respect to age and education.
Profile of Mood States (POMS):
During the test session, an abbreviated version of the POMS was filled out by the patient. This is a list of 32 adjectives clustered in 5 subscales (depression, anger, fatigue, vigor, and tension) by which subjects describe their mood during the preceding week.
